News

SIR's Carrier Advocacy Workgroup has developed two new evidence-based coverage letters for ttrium-90 (Y-90) transarterial radioembolization as a treatment for hepatocellular carcinoma and radiofrequency ablation of benign thyroid nodules.

These letters are free to SIR members and are created to help our members overturn carrier policy, denied authorizations and rejected claims. Visit the IR Business Center to download your copy today.